Aminocaproic Acids (EAC)

Subscribe to Selected New Research on Aminocaproic Acids

1050 relevant articles (38 outcomes, 117 trials/studies) found for this Drug

Description: A group of compounds that are derivatives of aminohexanoic acids.

Also Known As:

EAC; Aminocaproic Acid; Berlin-Chemie Brand of Aminocaproic Acid; Capralense; Capramol; Caproamin; Caprolest; Delagrange Brand of Aminocaproic Acid; Hemocaprol; Hexalense; Leurquin Brand of Aminocaproic Acid; Pharmachemie Brand of Aminocaproic Acid; Rottapharm Brand of Aminocaproic Acid; Sanofi Winthrop Brand of Aminocaproic Acid; Acid, Aminocaproic; Acids, Aminocaproic; Berlin Chemie Brand of Aminocaproic Acid

Relationship Network

Drug Context: Research Results

Organic Chemicals: 42

Carboxylic Acids: 62

Acyclic Acids

Caproates: 2

Amino Acids, Peptides, and Proteins

Amino Acids: 8786

Aminocaproic Acids: 1050

Experts

1.	Wang, Hong-Ping: 1 article (04/2008)
2.	Bao, Yi-Xi: 1 article (04/2008)
3.	Li, Jin: 1 article (04/2008)
4.	Liu, Jing: 1 article (04/2008)
5.	Zhu, Xuan: 1 article (04/2008)
6.	Karthikeyan, R: 1 article (01/2008)
7.	Balasubramanian, T: 1 article (01/2008)
8.	Somasundaram, S T: 1 article (01/2008)
9.	Sri Balasubashini, M: 1 article (01/2008)
10.	Karthigayan, S: 1 article (01/2008)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2008 - "A significant reduction in the incidence of cancer was observed in all groups that received the Viscum album extract compared with the EAC control group. " 09/01/2006 - "CONCLUSIONS: In patients with EAC, CCRT improved tumor response significantly compared with traditional CRT alone. " 10/01/2006 - "All these complexes increased the life span of the EAC-bearing mice, decreased their tumor volume and viable ascitic cell count as well as improved Hb, RBC and WBC counts. " 07/01/2003 - "CONCLUSIONS: The short- and long-term survival of patients with EAC has improved slightly in the United States over the past 25 yr. Some of the improvement may be related to an increase in the number of younger patients, and in cases with in situ and localized cancers. " 01/01/1981 - "Because lactate dehydrogenase-elevating virus (LDV) can be eliminated from tumor cells by passage in vitro, we attempted to grow EAC in tissue culture for several months and re-examined whether the inoculation of such cells could elevate plasma LDH activity induce IFN and enhance NK activity. " Order ALL the reference details at left...
2.	Hemorrhage 07/01/1983 - "The results of this study show a statistically significant reduction in the incidence of secondary hemorrhage in the patients receiving aminocaproic acid." 09/01/1997 - "It is as effective as systemic aminocaproic acid in reducing secondary hemorrhage. " 01/01/2007 - "This study investigates the efficacy of an aminocaproic-acid seal to prevent or reduce the risk of bleeding attendant to liver biopsies. " 11/01/1995 - "The efficacy of aminocaproic acid could not be determined due to the low incidence of hemorrhage. " 11/15/1991 - "In this study of a predominantly white population, patients had a relatively low incidence of secondary hemorrhage and did not demonstrate detectable benefit from aminocaproic acid administration. " Order ALL the reference details at left...
3.	Ascites 10/01/2007 - "One day after the last injection half of the mice with EAC were sacrificed and antitumor activity was assessed by means of ascites volume inhibition. " 07/01/1991 - "In the presence of ascites fluid in the culture medium, EAC cells progressed through G1 and S phases but accumulated in G2. " 01/01/1987 - "Cells of this substrain did not respond to (1) a highly purified growth inhibitor from bovine mammary gland, inhibiting the proliferation of two strains of the original EAC already at concentrations of 0.5-2.0 ng/ml, (2) inhibitory activities found in the ascites fluid of these sensitive strains and partially purified. " 01/01/1986 - "The observed differences in the agglutination patterns are discussed in view of the influence of the lipid content of EAC cells and the ascites fluid on ConA-induced cytoagglutination." 01/01/1983 - "The ascites fluid from EAC increases the anaerobic GL to 38, while it does not change the aerobic GL to 7 and diminishes the CR to 26. " Order ALL the reference details at left...
4.	Carcinoma (Carcinomatosis) 09/01/1994 - "Study on the cell membrane fluidity of carcinoma cells in EAC mice demonstrates that LWDHT can decrease the cell membrane fluidity, suggesting that it can inhibit division of carcinoma cells." 08/01/2008 - "The largest decrease was observed in mice pretreated with the Viscum album extract, although significantly reduced numbers of EAC cells were also observed in animals with developed carcinoma. " 08/01/2008 - "The hypothesis was tested that the Viscum album extract exhibits cytotoxic properties in Ehrlich carcinoma (EAC) cells in vivo due to the induction of oxidative stress. " 08/01/2007 - "In this paper, we present a patient who had bilateral SCC of EAC caused by radiotherapy for nasopharyngeal carcinoma. " 03/01/2007 - "Most authors advocate an aggressive surgical approach, which includes a form of a temporal bone resection, for the treatment of EAC carcinoma. " Order ALL the reference details at left...
5.	Cholesteatoma 12/01/2005 - "It was particularly effective in cholesteatomas in the EAC, attic cholesteatomas with an aerated mastoid, and in recurrent-type cholesteatomas. " 05/01/2009 - "RESULTS: At surgery for acquired atresia of the EAC, an EAC cholesteatoma was found in 3 of the 41 patients. " 02/01/2009 - "CONCLUSIONS: In CSEAC with cholesteatoma, the bony wall of EAC is most commonly involved. " 02/01/2009 - "Surgery allows removal of the cholesteatoma as well as EAC reconstruction and control biopsy." 02/01/2009 - "CONCLUSION: Secondary acquired cholesteatoma (through a bony defect of the EAC) may occur in patients previously treated for LCH. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tranexamic Acid (AMCA)
2.	Cisplatin (Platino)
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
4.	Vitamin E
5.	Cyclophosphamide (Cytoxan)
6.	Messenger RNA (mRNA)
7.	Glutamine (L-Glutamine)
8.	Melatonin
9.	Agar
10.	Glutamic Acid (Glutamate)

Related Therapies and Procedures

1.	Combination Drug Therapy (Combination Chemotherapy)
2.	Intraperitoneal Injections
3.	Transurethral Resection of Prostate (TURP)
4.	Extracorporeal Membrane Oxygenation (ECMO)
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>